Alpha-synuclein gene and Parkinson's disease

[1]  J. Seibyl,et al.  123I‐FP‐CIT SPECT [(123) I‐2β‐carbomethoxy‐3β‐(4‐iodophenyl)‐N‐(3‐fluoropropyl) nortropane single photon emission computed tomography] Imaging in a p.A53T α‐synuclein Parkinson's disease cohort versus Parkinson's disease , 2018, Movement disorders : official journal of the Movement Disorder Society.

[2]  E. Hatchwell,et al.  Genetic fine-mapping of the Iowan SNCA gene triplication in a patient with Parkinson’s disease , 2018, npj Parkinson's Disease.

[3]  S. Maji,et al.  Comparison of Kinetics, Toxicity, Oligomer Formation, and Membrane Binding Capacity of α-Synuclein Familial Mutations at the A53 Site, Including the Newly Discovered A53V Mutation. , 2018, Biochemistry.

[4]  M. Stamelou,et al.  Selective cognitive impairment and hyposmia in p.A53T SNCA PD vs typical PD , 2018, Neurology.

[5]  G. Koutsis,et al.  The different faces of the p. A53T alpha-synuclein mutation: A screening of Greek patients with parkinsonism and/or dementia , 2017, Neuroscience Letters.

[6]  Sonja W. Scholz,et al.  Insufficient evidence for pathogenicity of SNCA His50Gln (H50Q) in Parkinson's disease , 2017, Neurobiology of Aging.

[7]  M. Valencia,et al.  E46K α-synuclein pathological mutation causes cell-autonomous toxicity without altering protein turnover or aggregation , 2017, Proceedings of the National Academy of Sciences.

[8]  V. Sossi,et al.  Homozygous alpha-synuclein p.A53V in familial Parkinson's disease , 2017, Neurobiology of Aging.

[9]  R. Silva,et al.  Genetic Variants in SNCA and the Risk of Sporadic Parkinson's Disease and Clinical Outcomes: A Review , 2017, Parkinson's disease.

[10]  L. Kalia,et al.  α-Synuclein and Parkinsonism: Updates and Future Perspectives , 2017, Current Neurology and Neuroscience Reports.

[11]  M. Stamelou,et al.  Frontotemporal dementia as the presenting phenotype of p.A53T mutation carriers in the alpha-synuclein gene. , 2017, Parkinsonism & related disorders.

[12]  P. Carloni,et al.  Copper(II) and the pathological H50Q α-synuclein mutant: Environment meets genetics , 2017, Communicative & integrative biology.

[13]  Alexander K. Buell,et al.  Mutations associated with familial Parkinson’s disease alter the initiation and amplification steps of α-synuclein aggregation , 2016, Proceedings of the National Academy of Sciences.

[14]  M. Stamelou,et al.  Motor and Nonmotor Features of Carriers of the p.A53T Alpha‐Synuclein Mutation: A Longitudinal Study , 2016, Movement disorders : official journal of the Movement Disorder Society.

[15]  Wei-Xi Xiong,et al.  The heterozygous A53T mutation in the alpha-synuclein gene in a Chinese Han patient with Parkinson disease: case report and literature review , 2016, Journal of Neurology.

[16]  N. Hattori,et al.  Schizophrenia as a prodromal symptom in a patient harboring SNCA duplication. , 2016, Parkinsonism & related disorders.

[17]  A. Fasano,et al.  The Contursi Family 20 Years Later: Intrafamilial Phenotypic Variability of the SNCA p.A53T Mutation , 2016, Movement disorders : official journal of the Movement Disorder Society.

[18]  C. Cruchaga,et al.  Variants in GBA, SNCA, and MAPT influence Parkinson disease risk, age at onset, and progression , 2016, Neurobiology of Aging.

[19]  M. Martikainen,et al.  Clinical and imaging findings in Parkinson disease associated with the A53E SNCA mutation , 2015, Neurology: Genetics.

[20]  J. Hardy,et al.  Distinct clinical and neuropathological features of G51D SNCA mutation cases compared with SNCA duplication and H50Q mutation , 2015, Molecular Neurodegeneration.

[21]  Vincenzo Bonifati,et al.  Early-onset parkinsonism caused by alpha-synuclein gene triplication: Clinical and genetic findings in a novel family. , 2015, Parkinsonism & related disorders.

[22]  L. Vasconcellos,et al.  Parkinson disease: α-synuclein mutational screening and new clinical insight into the p.E46K mutation. , 2015, Parkinsonism & related disorders.

[23]  T. Golde,et al.  Divergent effects of the H50Q and G51D SNCA mutations on the aggregation of α‐synuclein , 2014, Journal of neurochemistry.

[24]  D. Vassilatis,et al.  Genetic assessment of familial and early‐onset Parkinson's disease in a Greek population , 2014, European journal of neurology.

[25]  Sebastian M. Armasu,et al.  Does α-synuclein have a dual and opposing effect in preclinical vs. clinical Parkinson's disease? , 2014, Parkinsonism & related disorders.

[26]  D. Hernandez,et al.  A 6.4 Mb duplication of the α-synuclein locus causing frontotemporal dementia and Parkinsonism: phenotype-genotype correlations. , 2014, JAMA neurology.

[27]  A. Miyashita,et al.  Clinical and neuroimaging features of patient with early-onset Parkinson's disease with dementia carrying SNCA p.G51D mutation. , 2014, Parkinsonism & related disorders.

[28]  D. Dickson,et al.  Diversity of pathological features other than Lewy bodies in familial Parkinson's disease due to SNCA mutations. , 2013, American journal of neurodegenerative disease.

[29]  Anna Potulska-Chromik,et al.  Novel A18T and pA29S substitutions in α-synuclein may be associated with sporadic Parkinson's disease. , 2013, Parkinsonism & related disorders.

[30]  C. Klein,et al.  The many faces of alpha‐synuclein mutations , 2013, Movement disorders : official journal of the Movement Disorder Society.

[31]  Sebastian M. Armasu,et al.  Genetic susceptibility loci, environmental exposures, and Parkinson's disease: a case-control study of gene-environment interactions. , 2013, Parkinsonism & related disorders.

[32]  M. Farrer,et al.  Alpha‐synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease , 2013, Movement disorders : official journal of the Movement Disorder Society.

[33]  A. Ariza,et al.  Alpha-Synuclein Posttranslational Modification and Alternative Splicing as a Trigger for Neurodegeneration , 2013, Molecular Neurobiology.

[34]  Christos Proukakis,et al.  A novel α-synuclein missense mutation in Parkinson disease , 2013, Neurology.

[35]  J. Hardy,et al.  α-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson’s disease and multiple system atrophy? , 2013, Acta Neuropathologica.

[36]  L. Stefanis.  α-Synuclein in Parkinson's disease. , 2012, Cold Spring Harbor perspectives in medicine.

[37]  J. Zarranz,et al.  Initial neuropsychological impairments in patients with the E46K mutation of the α-synuclein gene (PARK 1) , 2011, Journal of the Neurological Sciences.

[38]  Janel O. Johnson,et al.  Clinical features, with video documentation, of the original familial lewy body parkinsonism caused by α‐synuclein triplication (Iowa kindred) , 2011, Movement disorders : official journal of the Movement Disorder Society.

[39]  R. Krüger,et al.  First appraisal of brain pathology owing to A30P mutant alpha‐synuclein , 2010, Annals of neurology.

[40]  M. Farrer,et al.  A Swedish family with de novo alpha-synuclein A53T mutation: evidence for early cortical dysfunction. , 2009, Parkinsonism & related disorders.

[41]  M. Farrer,et al.  Expanding the clinical phenotype of SNCA duplication carriers , 2009, Movement disorders : official journal of the Movement Disorder Society.

[42]  D. Costa,et al.  (123)I-FP-CIT SPET striatal uptake in parkinsonian patients with the alpha-synuclein (G209A) mutation A. , 2008, Hellenic journal of nuclear medicine.

[43]  Y. Sohn,et al.  Analysis of PARK genes in a Korean cohort of early-onset Parkinson disease , 2008, Neurogenetics.

[44]  B. Jeon,et al.  α-Synuclein gene duplication is present in sporadic Parkinson disease , 2008, Neurology.

[45]  D. Cordato,et al.  Dementia with Lewy bodies in an elderly Greek male due to α-synuclein gene mutation , 2006, Journal of Clinical Neuroscience.

[46]  L. Petrucelli,et al.  Gene dosage and pathogenesis of Parkinson's disease. , 2005, Trends in molecular medicine.

[47]  Philippe Amouyel,et al.  α-synuclein locus duplication as a cause of familial Parkinson's disease , 2004, The Lancet.

[48]  A. Singleton,et al.  Association between cardiac denervation and parkinsonism caused by α‐synuclein gene triplication , 2004 .

[49]  J. Hoenicka,et al.  The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia , 2004, Annals of neurology.

[50]  Janel O. Johnson,et al.  α-Synuclein Locus Triplication Causes Parkinson's Disease , 2003, Science.

[51]  J. Trojanowski,et al.  Concurrence of α-synuclein and tau brain pathology in the Contursi kindred , 2002, Acta Neuropathologica.

[52]  A. Lees,et al.  Clinical features of parkinsonian patients with the α‐synuclein (G209A) mutation , 2001 .

[53]  R. Krüger,et al.  Evaluation of the γ-synuclein gene in German Parkinson's disease patients , 2001, Neuroscience Letters.

[54]  Glenda M. Halliday,et al.  Clinical and pathological features of a parkinsonian syndrome in a family with an Ala53Thr α‐synuclein mutation , 2001 .

[55]  Vesna Sossi,et al.  Prevalence of epilepsy in rural Bolivia , 1999, Neurology.

[56]  G. Hadjigeorgiou,et al.  Mutated α-synuclein gene in two Greek kindreds with familial PD: Incomplete penetrance? , 1999, Neurology.

[57]  Olaf Riess,et al.  AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease , 1998, Nature Genetics.

[58]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[59]  H. Kaufmann,et al.  Cardiac sympathetic denervation in symptomatic and asymptomatic carriers of the E46K mutation in the α synuclein gene. , 2013, Parkinsonism & related disorders.